During ESMO 2023, oncologists came together to discuss lung cancer data emerging from the congress and the potential implications for clinical practice in the US, Japan and China. The meeting co-hosts each shared their views on key data from three abstracts presented during ESMO before opening up the discussion to the panel. Watch the on-demand video to hear what they had to say.

 

Panel

  • Prof. Li Zhang, Sun Yat-sen University Cancer Center, Guangzhou, China

  • Prof. Tetsuya Mitsudomi, Kindai University, Osaka, Japan

  • Prof. Pasi A. Jänne, Dana-Farber Cancer Institute, Boston (MA), USA

  • Prof. Xiuning Le, MD Anderson Cancer Center, Houston (TX), USA


Clinical Takeaways

  • Updated results show that BL-B01D1 has potential in treating NSCLC patients who progressed after standard therapies.
  • In the KEYNOTE-671, perioperative pembrolizumab regimen significantly improves overall survival in resectable NSCLC versus placebo.
  • In the FLAURA2 trial, combining platinum-pemetrexed with osimertinib improves PFS in EGFR-mutated advanced NSCLC patients as compared to osimertinib alone, with a manageable safety profile.

 

Trials

  • BL-B01D1 bispecific EGFRxHER3 antibody drug conjugate trial
  • KEYNOTE-671
  • APG-1252 with Osimertinib for EGFR-mutant NSCLC
  • FLAURA2
  • RAMOSE
  • MARIPOSA

  • Inform oncologists about the latest clinical insights in lung oncology presented during EMSO 2023
  • Understand the impact of the latest clinical insights on clinical practice in the US, Japan and China

Programme summary
  • clock Duration 43 MIN
  • clock HCPs enrolled 504 HCPs
  • clock Language(s) flag
Play the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from SystImmune and BeiGene Europe.
I agree that this educational programme:

Was valuable to me

1/4

Other programmes of interest

podcast Podcast
Oncology 
Prostate cancer: Pre-analytical phase challenges and biomarker testing

Moderated by the Oncology Brothers. Episode 1 of a 3-part video podcast series

Experts
Dr Alexander Wyatt, Dr Petros Grivas, Oncology Brothers (Moderators)
Endorsed by
AMP NASPCC
  • download Downloadable
    Resouces
  • clock 30 MIN
  • calendar Nov 2023

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.
tweetorial Tweetorial
Oncology 
Tweetorial video: Navigating ER+ metastatic breast cancer

Explore a patient case from testing, diagnosis and treatment

Experts
Dr Paolo Tarantino
Endorsed by
GRASP
  • clock 9 MIN
  • calendar Nov 2023

Educational programme supported by an independent medical education grant from Menarini Stemline Oncology
interactive-patient-case Interactive patient case

Episode

2

of 2

episode
Oncology 
Oral SERDs: New Endocrine Therapy Options in ER+ Advanced or Metastatic Breast Cancer – Part 2

An interactive patient case video series from breast cancer specialists

Experts
Prof. Valentina Guarneri
Endorsed by
GRASP
  • clock 15 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from Menarini Stemline Oncology
conference-update Conference update
Oncology 
GI highlights from ESMO 2023

An expert panel discussion hosted by COR2ED and eChinaHealth

  • clock 50 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from BeiGene Europe and SystImmune.
conference-update Conference update
Oncology 
RCC Update from ESMO 2023

How will the latest data impact clinical practice?

Experts
Prof. Laurence Albiges
  • download Downloadable
    Resouces
  • clock 4 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from Eisai Europe Limited.
conference-update Conference update
Oncology 
Precision Oncology Update From ESMO 2023

How will the latest data impact clinical practice?

Experts
Dr Philipp Ivanyi
  • download Downloadable
    Resouces
  • clock 3 MIN
  • calendar Oct 2023

Educational programme supported by an independent medical education grant from Bayer.